Document Detail

Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin.
MedLine Citation:
PMID:  22074664     Owner:  NLM     Status:  Publisher    
Polyethylene glycol (PEG)-conjugated hyaluronic acid-ceramide (HACE) was synthesized for the preparation of doxorubicin (DOX)-loaded HACE-PEG-based nanoparticles, 160 nm in mean diameter with a negative surface charge. Greater uptake of DOX from these HACE-PEG-based nanoparticles was observed in the CD44 receptor highly expressed SCC7 cell line, compared to results from the CD44-negative cell line, NIH3T3. A strong fluorescent signal was detected in the tumor region upon intravenous injection of cyanine 5.5-labeled nanoparticles into the SCC7 tumor xenograft mice; the extended circulation time of the HACE-PEG-based nanoparticle was also observed. Pharmacokinetic study in rats showed a 73.0% reduction of the in vivo clearance of DOX compared to the control group. The antitumor efficacy of the DOX-loaded HACE-PEG-based nanoparticles was also verified in a tumor xenograft mouse model. DOX was efficiently delivered to the tumor site by active targeting via HA and CD44 receptor interaction and by passive targeting due to its small mean diameter (<200 nm). Moreover, PEGylation resulted in prolonged nanoparticle circulation and reduced DOX clearance rate in an in vivo model. These results therefore indicate that PEGylated HACE nanoparticles represent a promising anticancer drug delivery system for cancer diagnosis and therapy.
Hyun-Jong Cho; In-Soo Yoon; Hong Yeol Yoon; Heebeom Koo; Yu-Jin Jin; Seung-Hak Ko; Jae-Seong Shim; Kwangmeyung Kim; Ick Chan Kwon; Dae-Duk Kim
Related Documents :
21954434 - Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in h...
8509214 - Differential chemosensitivity of local and metastatic human gastric cancer after orthot...
11501504 - Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated ...
21841164 - Cbs9106 is a novel reversible oral crm1 inhibitor with crm1 degrading activity.
2174304 - Cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovar...
25131324 - Laparoscopic reduced port surgery for schwannoma of the sigmoid colon: a case report.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-11-8
Journal Detail:
Title:  Biomaterials     Volume:  -     ISSN:  1878-5905     ISO Abbreviation:  -     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8100316     Medline TA:  Biomaterials     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles.
Next Document:  Three-dimensional paper-based electrochemiluminescence immunodevice for multiplexed measurement of b...